Skip to content

Why MSLs Are Your Best Intelligence Network

For years, pharma has treated Medical Science Liaisons as a necessary expense. A compliance box to check. A scientific resource to keep separate from commercial. A field team that’s “important” — but hard to measure. That mindset is not just outdated. It’s strategically reckless. Because when used correctly, MSLs are one of the most valuable assets a pharma brand has — not just for physicians, but for the brand itself.

MSLs Are Not a Buffer Between Sales and Compliance

Too many organizations still quietly view MSLs as the safe alternative to sales reps.

“Let the MSL handle the hard science.”
“Let the MSL answer off-label questions.”
“Let the MSL clean up confusion.”

That’s a waste of the role.

MSLs are not there to protect the brand from regulatory risk. They are there to elevate the scientific conversation. And when that conversation improves, so does prescribing confidence.

Physicians don’t need another promotional voice. They need clarity.

For Physicians: MSLs Reduce Clinical Uncertainty

Most physicians are overwhelmed. New data. New indications. New safety updates. New mechanisms of action.

In crowded categories — oncology, immunology, cardiometabolic — the data doesn’t just pile up. It conflicts.

Think about what’s happened in obesity and diabetes care with GLP-1s like Ozempic and Wegovy. The science evolves quickly. Outcomes trials expand indications. Safety narratives shift in the media. Patients walk in with internet printouts.

A sales rep can’t unpack that complexity. An MSL can.

A strong MSL:

  • Interprets clinical data without spin
  • Explains trial design strengths and weaknesses
  • Discusses patient selection nuances
  • Clarifies real-world evidence vs. randomized data
  • Bring peer insights back into the organization

That’s not promotion. That’s decision support. And physicians value that.

For Pharma Brands: MSLs Are Your Best Intelligence Network

Here’s what many commercial teams miss:

MSLs hear what physicians actually think.

Not what they tell a rep in a five-minute hallway conversation.
Not what shows up in a market research survey.

They hear:

  • Why does a physician hesitate to switch therapy
  • What safety signal is causing concern
  • Where patient adherence is failing
  • What competing data is being discussed in academic circles

In areas like oncology, consider how complex treatment sequencing has become in diseases like HER2-positive breast cancer, with therapies such as Herceptin — subtle shifts in guideline interpretation can shift market share quickly. If your MSL team isn’t feeding that back in real time, you’re flying blind.

MSLs are not just scientific ambassadors.
They are early warning systems.

The Strategic Mistake: Keeping MSL Insights in a Silo

The biggest missed opportunity isn’t underutilizing MSLs in the field. It’s under-leveraging their insight internally.

Too often:

  • MSL reports sit in CRM systems that no one reads.
  • Commercial teams don’t understand what to ask for.
  • Leadership views medical and commercial as parallel tracks instead of interconnected strategy engines.

If your digital team is building physician websites, and your MSLs are hearing confusion about dosing, why isn’t that content changing?

If your brand team is planning a launch, and MSLs are hearing skepticism about trial endpoints, why isn’t messaging adjusting?

The wall between medical and commercial should protect compliance — not prevent intelligence flow.

Measuring MSL Value the Wrong Way

You cannot measure MSL value the same way you measure sales reps.

Volume of visits? Meaningless.
Number of slide decks delivered? Irrelevant.

The value of an MSL is measured in:

  • Depth of scientific engagement
  • Quality of insights captured
  • Influence on thought leaders
  • Internal strategic impact

If the only KPI is “number of interactions,” you’ve reduced a strategic role to an activity metric.

And pharma already has enough of those.

The Real Value: Credibility

At a time when trust in pharma is fragile, credibility matters more than ever.

MSLs represent the part of the organization that prioritizes science over selling. That distinction matters to physicians.

When done right, MSL engagement:

  • Increases physician confidence
  • Reduces inappropriate prescribing
  • Improves patient selection
  • Strengthens long-term brand perception

Not because they push product. But because they elevate understanding. If your organization views MSLs as a cost center, you’re underestimating them. If you view them as a compliance shield, you’re misusing them. But if you view them as scientific strategists embedded in the field — connecting physicians, evidence, and internal teams — they become one of your most powerful competitive advantages. And in today’s market, advantage doesn’t come from louder promotion.It comes from smarter science.

Topics:

Richard Meyer

I’m Richard Meyer — a 25 year healthcare marketing strategist and writer focused on the intersection of direct-to-consumer marketing, healthcare economics, and human behavior.I started Work of DTC Marketing because too much of the conversation around pharma and healthcare marketing is either overly promotional, overly technical, or completely disconnected from how the system actually works.Here, I write about what DTC really does, how incentives drive behavior inside healthcare organizations, why patients are often treated like revenue streams instead of people, and why “best practices” are frequently just recycled assumptions.My background spans digital marketing, public relations, and healthcare strategy, and my approach is pragmatic, skeptical of hype, and grounded in data and lived experience. I’m less interested in what sounds good in a deck and more interested in what actually changes outcomes — for companies, doctors, and especially patients.

Leave a Reply

Send this to a friend